Radioiodine therapy in non-toxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH)

References

• Hegedüs L. The thyroid nodule. N Engl J Med 2004; 351: 1764–71
   PubMed Web of Science ®Google Scholar
• Brix TH, Kyvik KO, Hegedüs L. Major role of genes in the etiology of simple goiter in females: A population-based twin study. J Clin Endocrinol Metab 1999; 84: 3071–5
   PubMedGoogle Scholar
• Knudsen N, Bülow I, Jørgensen T, Laurberg P, Ovesen L, Perrild H. Goitre prevalence and thyroid abnormalities at ultrasonography: A comparative epidemiological study in two regions with slightly different iodine status. Clin Endocrinol (Oxf) 2000; 53: 479–85
   PubMed Web of Science ®Google Scholar
• Bonnema SJ, Nielsen VE, Hegedüs L. Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. Eur J Endocrinol 2004; 150: 439–45
   PubMedGoogle Scholar
• Hegedüs L, Bonnema SJ, Bennedbæk FN. Management of simple nodular goiter: Current status and future perspectives. Endocr Rev 2003; 24: 102–32
   PubMed Web of Science ®Google Scholar
• Gittoes NJ, Miller MR, Daykin J, Sheppard MC, Franklyn JA. Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. Br Med J 1996; 312: 484
   PubMedGoogle Scholar
• Elte JW, Bussemaker JK, Haak A. The natural history of euthyroid multinodular goitre. Postgrad Med J 1990; 66: 186–90
   PubMedGoogle Scholar
• Hamburger JI. Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 1980; 50: 1089–93
   PubMed Web of Science ®Google Scholar
• Wiener JD, de Vries AA. On the natural history of Plummer's disease. Clin Nucl Med 1979; 4: 181–90
   PubMedGoogle Scholar
• Bonnema SJ, Bennedbæk FN, Wiersinga WM, Hegedüs L. Management of the nontoxic multinodular goitre: A European questionnaire study. Clin Endocrinol (Oxf) 2000; 53: 5–12
   PubMed Web of Science ®Google Scholar
• Bonnema SJ, Bennedbæk FN, Ladenson PW, Hegedüs L. Management of the nontoxic multinodular goiter: A North American Survey. J Clin Endocrinol Metab 2002; 87: 112–7
   PubMed Web of Science ®Google Scholar
• Bhagat MC, Dhaliwal SS, Bonnema SJ, Hegedüs L, Walsh JP. Differences between endocrine surgeons and endocrinologists in the management of non-toxic multinodular goitre. Br J Surg 2003; 90: 1103–12
   PubMedGoogle Scholar
• Kahaly G, Dienes HP, Beyer J, Hommel G. Randomized, double blind, placebo-controlled trial of low dose iodide in endemic goiter. J Clin Endocrinol Metab 1997; 82: 4049–53
   PubMedGoogle Scholar
• Hintze G, Kobberling J. Treatment of iodine deficiency goiter with iodine, levothyroxine or a combination of both. Thyroidology 1992; 4: 37–40
   PubMedGoogle Scholar
• Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid 2001; 11: 493–500
   PubMed Web of Science ®Google Scholar
• Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 1990; 336: 193–7
   PubMed Web of Science ®Google Scholar
• Bongers H, Hotze LA, Schmitz R, Joseph K. LT4-monopreparation versus LT4-LT3-compound preparation in the treatment of diffuse endemic goitre. Acta Endocrinol (Copenh) 1986; 113: 242–8
   PubMedGoogle Scholar
• Perrild H, Hansen JM, Hegedüs L, Rytter L, Holm B, Gundtofte E, et al. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh) 1982; 100: 382–7
   PubMedGoogle Scholar
• Hansen JM, Kampmann J, Madsen SN, Skovsted L, Solgaard S, Grytter C, et al. L-thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic determination of thyroid volume. Clin Endocrinol (Oxf) 1979; 10: 1–6
   PubMedGoogle Scholar
• Wilders-Truschnig MM, Warnkross H, Leb G, Langsteger W, Eber O, Tiran A, et al. The effect of treatment with levothyroxine or iodine on thyroid size and thyroid growth stimulating immunoglobulins in endemic goitre patients. Clin Endocrinol (Oxf) 1993; 39: 281–6
   PubMedGoogle Scholar
• Wesche MF, Tiel-Van Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86: 998–1005
   PubMedGoogle Scholar
• Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J Clin Endocrinol Metab 1996; 81: 4278–89
   PubMed Web of Science ®Google Scholar
• Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet 2001; 358: 861–5
   PubMed Web of Science ®Google Scholar
• Ozbas S, Kocak S, Aydintug S, Cakmak A, Demirkiran MA, Wishart GC. Comparison of the complications of subtotal, near total and total thyroidectomy in the surgical management of multinodular goitre. Endocr J 2005; 52: 199–205
   PubMed Web of Science ®Google Scholar
• al Suliman NN, Ryttov NF, Qvist N, Blichert-Toft M, Graversen HP. Experience in a specialist thyroid surgery unit: A demographic study, surgical complications, and outcome. Eur J Surg 1997; 163: 13–20
   PubMedGoogle Scholar
• Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: Prospective multicenter study in Germany. World J Surg 2000; 24: 1335–41
   PubMed Web of Science ®Google Scholar
• Abdel Rahim AA, Ahmed ME, Hassan MA. Respiratory complications after thyroidectomy and the need for tracheostomy in patients with a large goitre. Br J Surg 1999; 86: 88–90
   PubMedGoogle Scholar
• Geelhoed GW. Tracheomalacia from compressing goiter: Management after thyroidectomy. Surgery 1988; 104: 1100–8
   PubMedGoogle Scholar
• Netterville JL, Coleman SC, Smith JC, Smith MM, Day TA, Burkey BB. Management of substernal goiter. Laryngoscope 1998; 108: 1611–7
   PubMedGoogle Scholar
• Torre G, Borgonovo G, Amato A, Arezzo A, Ansaldo G, De Negri A, et al. Surgical management of substernal goiter: Analysis of 237 patients. Am Surg 1995; 61: 826–31
   PubMedGoogle Scholar
• Hegedüs L, Nygaard B, Hansen JM. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified?. J Clin Endocrinol Metab 1999; 84: 756–60
   PubMedGoogle Scholar
• Feldkamp J, Seppel T, Becker A, Klisch A, Schlaghecke R, Goretzki PE, et al. Iodide or L-thyroxine to prevent recurrent goiter in an iodine- deficient area: Prospective sonographic study. World J Surg 1997; 21: 10–4
   PubMedGoogle Scholar
• Pappalardo G, Guadalaxara A, Frattaroli FM, Illomei G, Falaschi P. Total compared with subtotal thyroidectomy in benign nodular disease: Personal series and review of published reports. Eur J Surg 1998; 164: 501–6
   PubMedGoogle Scholar
• Døssing H, Bennedbæk FN, Karstrup S, Hegedüs L. Benign solitary solid cold thyroid nodules: US-guided interstitial laser photocoagulation–initial experience. Radiology 2002; 225: 53–7
   PubMed Web of Science ®Google Scholar
• Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: Effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999; 84: 3636–41
   PubMed Web of Science ®Google Scholar
• Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med 1994; 121: 757–62
   PubMed Web of Science ®Google Scholar
• Le Moli R, Wesche MF, Tiel-Van Buul MM, Wiersinga WM. Determinants of long term outcome of radioiodine therapy of sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1999; 50: 783–9
   PubMedGoogle Scholar
• Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Søe-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. Br Med J 1993; 307: 828–32
   PubMed Web of Science ®Google Scholar
• Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999; 159: 1364–8
   PubMed Web of Science ®Google Scholar
• Bonnema SJ, Knudsen DU, Bertelsen H, Mortensen J, Andersen PB, Bastholt L, et al. Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging. Thyroid 2002; 12: 313–7
   PubMedGoogle Scholar
• Jarløv AE, Hegedüs L, Kristensen LØ, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile?. Clin Endocrinol (Oxf) 1995; 43: 325–9
   PubMed Web of Science ®Google Scholar
• Nygaard B, Knudsen JH, Hegedüs L, Veje A, Hansen JE. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 1997; 82: 2926–30
   PubMed Web of Science ®Google Scholar
• Nygaard B, Faber J, Veje A, Hegedüs L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid 1999; 9: 477–81
   PubMed Web of Science ®Google Scholar
• Nygaard B, Metcalfe RA, Phipps J, Weetman AP, Hegedüs L. Graves’ disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter. J Endocrinol Invest 1999; 22: 481–5
   PubMedGoogle Scholar
• Nygaard B, Faber J, Hegedüs L. Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin Endocrinol (Oxf) 1994; 41: 715–8
   PubMedGoogle Scholar
• Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: A population-based cohort study. Lancet 1999; 353: 2111–5
   PubMed Web of Science ®Google Scholar
• Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998; 280: 347–55
   PubMed Web of Science ®Google Scholar
• Albino CC, Mesa CO, Jr, Olandoski M, Ueda CE, Woellner LC, Goedert CA, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005; 90: 2775–80
   PubMed Web of Science ®Google Scholar
• Nielsen VE, Bonnema SJ, Boel-Jørgensen H, Veje A, Hegedüs L. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: An evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab 2005; 90: 79–83
   PubMed Web of Science ®Google Scholar
• Huysmans DA, Nieuwlaat W, Erdtsieck J, Schellekens AP, Bus JW, Bravenboer B, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodine uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000; 85: 3592–6
   PubMed Web of Science ®Google Scholar
• Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, Corstens FH, Huysmans DA. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001; 86: 5330–6
   PubMed Web of Science ®Google Scholar
• Nieuwlaat WA, Huysmans DA, Van Den Bosch HC, Sweep CG, Ross HA, Corstens FH, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003; 88: 3121–9
   PubMed Web of Science ®Google Scholar
• Silva MN, Rubio IG, Romao R, Gebrin EM, Buchpiguel C, Tomimori E, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 2004; 60: 300–8
   PubMed Web of Science ®Google Scholar
• Nielsen VE, Bonnema SJ, Hegedüs L. The effects of recombinant human thyrotropin, in normal subjects and patients with goitre. Clin Endocrinol (Oxf) 2004; 61: 655–63
   PubMedGoogle Scholar
• Nieuwlaat WA, Hermus AR, Ross HA, Buijs WC, Edelbroek MA, Bus JW, et al. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. J Nucl Med 2004; 45: 626–33
   PubMedGoogle Scholar
• Nielsen VE, Bonnema S, Hegedüs L, Grupe P, Boel-Jørgensen H. Recombinant human thyrotropin prior to radioiodine therapy improves the size reduction of non-toxic nodular goiter: A prospective randomized double-blinded trial. Thyroid 2005; 15(Suppl 1)026
   Google Scholar
• Cubas ER, Paz GJ, Boeving A, Santos CM, Piovesan G, Carvalho G, et al. Treatment of multinodular goiter with low doses of recombinant human TSH before a low and fixed dose of 131I: A randomized, double-blinded, placebo-controlled study. Thyroid 2005; 15(Suppl 1)O130
   Google Scholar
• Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001; 86: 1660–4
   PubMed Web of Science ®Google Scholar
• Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001; 86: 5148–51
   PubMed Web of Science ®Google Scholar
• Goffman T, Ioffe V, Tuttle M, Bowers JT, Mason ME. Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma. Thyroid 2003; 13: 827–30
   PubMedGoogle Scholar
• Nielsen VE, Bonnema SJ, Hegedüs L. Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: A randomized, double-blind, cross-over trial. J Clin Endocrinol Metab 2004; 89: 2242–7
   PubMed Web of Science ®Google Scholar
• Nielsen VE, Bonnema S, Hegedüs L. Transient goiter enlargement after administration of 0.3 mg recombinant human thyrotropin in patients with nontoxic nodular goiter. A randomized, double-blind, cross-over trial. J Clin Endocrinol Metab 2005 (in press).
   Google Scholar
• Hegedüs L, Hansen BM, Knudsen N, Hansen JM. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. Br Med J 1988; 297: 661–2
   PubMed Web of Science ®Google Scholar
• Wesche MF, Buul MM, Smits NJ, Wiersinga WM. Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter. Eur J Endocrinol 1995; 132: 86–7
   PubMed Web of Science ®Google Scholar
• Verelst J, Bonnyns M, Glinoer D. Radioiodine therapy in voluminous multinodular non-toxic goitre. Acta Endocrinol (Copenh) 1990; 122: 417–21
   PubMedGoogle Scholar
• De Klerk JM, Van Isselt JW, van Dijk A, Hakman ME, Pameijer FA, Koppeschaar HP, et al. Iodine-131 therapy in sporadic nontoxic goiter. J Nucl Med 1997; 38: 372–6
   PubMedGoogle Scholar